CLASS II Drug recall · Reported 27 Nov 2013 · FDA Enforcement Report

Aldactone (spironolactone) tablets, USP, 100 mg recalled

Pfizer Us Pharmaceutical Group is recalling Aldactone (spironolactone) tablets, USP, 100 mg, distributed nationwide in the US. The recall was initiated on 4 Sep 2013 and the FDA has classified it as Class II.

Check your package

Lot, batch or date codesLot #: V121573, Exp 05/17
NDC0025-1001, 0025-1041, 0025-1031
UPC0300251001314, 0300251031311, 0300251041310
Quantity recalled31 bottles

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

Recall details

Recall number
D-014-2014
FDA event ID
66124
Recalling firm
Pfizer Us Pharmaceutical Group, New York, NY
Manufacturer
Pfizer Laboratories Div Pfizer Inc
Classification
Class II
Status
Terminated
Recall initiated
4 Sep 2013
FDA classified
20 Nov 2013
Reported
27 Nov 2013
Type
Voluntary: Firm initiated
Customers notified by
Letter
Reason category
Potency & Assay

Timeline

4 Sep 2013Recall initiated by company
20 Nov 2013Classified by FDA+77 days
27 Nov 2013Published in enforcement report+7 days

Companies usually start a recall weeks before the FDA classifies and publishes it; the gap above is that lag.

Reason for recall

Marketed without an Approved NDA/ANDA: This recall is being initiated because of changes to the dissolution profile in distributed lots resulting from a manufacturing site change. There is currently no approved application supporting the alternate manufacturing site.

Potency and specification recalls happen when a batch tests outside its approved limits for strength, purity or dissolution, which can mean the dose delivered is higher or lower than labelled.

Product as listed by the FDA

Aldactone (spironolactone) tablets, USP, 100 mg, 100-count bottles, Rx only, Distributed by G.D. Searle, Division of Pfizer Inc, NY, NY 10017, NDC 0025-1031-31

Where it was distributed

US Nationwide

Nationwide

Questions about this recall

Why was it recalled?

Marketed without an Approved NDA/ANDA: This recall is being initiated because of changes to the dissolution profile in distributed lots resulting from a manufacturing site change. There is currently no approved application supporting the alternate manufacturing site.

Which lots are affected?

Lot #: V121573, Exp 05/17

Where was it sold?

US Nationwide

What should I do if I have it?

Check the lot number on your package against the affected lots. If it matches, contact the pharmacy that dispensed it or your prescriber before stopping any medication.

What does Class II mean?

Class II means the product may cause temporary or medically reversible health problems, or the probability of serious harm is remote.

Read the official FDA notice · Source record retrieved 26 Sep 2026. The FDA describes openFDA data as unvalidated; the official notice takes precedence. This page reports the record and gives no medical advice.

More recalls from Pfizer Us Pharmaceutical Group

All 4

Other Spironolactone recalls

All 8